Zenas BioPharma, Inc. (NasdaqGS: ZBIO)
Health Care · Biotechnology · US
$33.04
+11.96% today · +70.8% 1Y
Zenas BioPharma, Inc. (NasdaqGS: ZBIO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.92B and employs 167 people.
Over the last twelve months the share price has gained 70.8%, trading between 13.50 and 44.60.
Tweenvest scores Zenas BioPharma, Inc. across four factors: quality 26/100, value 47/100. Its strongest factor is value.
ZBIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.92B
- Revenue (TTM)
- $1.00M
- P/E
- —
- EPS
- -8.82
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $44.60
- 52-week low
- $13.50
- Avg volume (3M)
- —
- Shares outstanding
- 65.18M
- Employees
- 167
- Next earnings
- —
About Zenas BioPharma, Inc.
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
- ISIN
- US98937L1052
- Founded
- 2019
- Listed since
- Sep 13, 2024
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.